Single-Arm Trial of Carotid Stenting for Carotid Stenosis (Timing Trial)
A Prospective, Multicenter, Single-arm, Target Value Clinical Trial to Evaluate the Efficacy and Safety of the Carotid Artery Stent System in the Treatment of Carotid Artery Stenosis
This is a prospective, multicenter, single-group, target value clinical trial planning to enroll 208 eligible subjects. Participants will be treated with the investigational carotid artery stent system and followed up at discharge, 30 days, 6 months, and 12 months postoperatively to evaluate the safety and efficacy of the device for endovascular treatment of carotid artery stenosis.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Liqun Jiao
- 전화번호: 010-83198277
- 이메일: 13911224991@139.com
연구 장소
-
-
-
Beijing, 중국
- Xuanwu Hospital
-
연락하다:
- Liqun Jiao
- 전화번호: 010-83198277
- 이메일: 13911224991@139.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
General Inclusion Criteria (all must be satisfied):
- Age ≥18 years, either sex.
- Preoperative carotid duplex ultrasound (DUS) confirms stenosis of the common carotid artery (CCA), internal carotid artery (ICA), or carotid bifurcation, and the subject is deemed suitable for endovascular intervention.
- Intraoperative digital subtraction angiography (DSA) confirms symptomatic carotid artery stenosis ≥50% or asymptomatic carotid artery stenosis ≥80% (measured by NASCET criteria). Symptomatic is defined as a non-disabling ischemic stroke or transient ischemic attack (TIA), including cerebral hemisphere events or amaurosis fugax, occurring within 6 months prior to the procedure.
- Reference vessel diameter at the target lesion ranges from 3.5 mm to 9.5 mm.
- Voluntarily participates in this trial and signs the informed consent form.
CEA High-Risk Inclusion Criteria (at least one criterion must be met):
Clinical High-Risk Factors:
- Age >80 years.
- Low cardiac output [left ventricular ejection fraction (LVEF) <30%].
- Untreated or poorly controlled arrhythmia (recurrent despite standard medical therapy or other treatment).
- Cardiac insufficiency (New York Heart Association Class III-IV).
- Recent myocardial infarction (occurring between 72 hours and 30 days prior to the procedure).
- Unstable angina (Canadian Cardiovascular Society Class 3-4).
- Severe chronic obstructive pulmonary disease (COPD), defined as forced expiratory volume in 1 second (FEV1) <50% of predicted value.
Anatomic High-Risk Factors:
- Restenosis after prior carotid endarterectomy (CEA).
- Contralateral carotid artery occlusion.
- Tandem carotid artery lesions.
- Carotid artery dissection.
- Pseudoaneurysm.
Exclusion Criteria:
- Target lesion caused by carotid arteritis.
- Target lesion located at the ostium of the common carotid artery.
- Severe, long-segment calcification or severe tortuosity at the target lesion preventing adequate stent delivery.
- Target lesion is a complete occlusion.
- Presence of large acute or subacute thrombus, or arteriovenous malformation adjacent to the target lesion.
- Requirement for concurrent stenting or stenting in other territories (intracranial or extracranial) within 30 days after the procedure.
- Intracranial hemorrhage within 3 months prior to the procedure.
- Large-scale ischemic stroke within 30 days prior to the procedure.
- Known intracranial aneurysm that cannot be treated in advance.
- Known coagulation disorder (activated partial thromboplastin time [APTT] >3 times the upper limit of normal) or abnormal bleeding diathesis.
- Known contraindication to heparin or antiplatelet agents.
- Known allergy to device components, contrast agent, or related materials.
- Severe hepatic or renal insufficiency (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >5 times the upper limit of normal; serum creatinine >3 times the upper limit of normal).
- Uncontrolled severe hypertension (persistent systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg).
- Preoperative bradycardia (heart rate <40 beats per minute).
- Preoperative modified Rankin Scale (mRS) score ≥3.
- Malignant tumor with extensive metastasis.
- Currently participating in another drug or device clinical trial.
- Pregnant or lactating women, or women planning pregnancy within 1 year.
- Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Carotid Artery Stent System
|
All participants will undergo carotid artery stenting (CAS). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of In-Stent Restenosis (ISR)
기간: through study completion, an average of 1 year
|
Restenosis is defined as ≥50% diameter stenosis occurring within the stent or within 5 mm of the proximal or distal stent edge of the target carotid artery, as assessed by carotid duplex ultrasound (DUS). |
through study completion, an average of 1 year
|
|
Incidence of Major Adverse Events (MAE)
기간: through study completion, an average of 1 year
|
Major adverse events (MAE) are defined as the composite incidence of: (1) death, stroke (ischemic or hemorrhagic), or myocardial infarction (MI) occurring within 30 days after the procedure; and (2) death or ipsilateral ischemic stroke of the target vessel occurring from 31 to 365 days after the procedure. |
through study completion, an average of 1 year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Device Success Rate
기간: Intraoperative
|
Defined as the percentage of enrolled subjects in whom device success is achieved. Device success is defined as successful implantation (including delivery, deployment, and expansion) of the stent covering the target lesion, with successful retrieval of the delivery system. |
Intraoperative
|
|
Procedural Success Rate
기간: Perioperative
|
Defined as the percentage of enrolled subjects in whom procedural success is achieved. Procedural success is defined as successful implantation of the stent, with post-procedure angiography demonstrating ≤30% residual stenosis at the target lesion, and freedom from major adverse events (MAE; defined as all-cause death, stroke, or myocardial infarction) prior to hospital discharge. |
Perioperative
|
|
Incidence of In-Stent Restenosis (ISR)
기간: 6 months
|
Defined as the percentage of enrolled subjects who develop ISR at 6 months post-procedure. ISR is defined as restenosis within the stent or within 5 mm proximal or distal to the stent edge of the target carotid artery, as assessed by carotid duplex ultrasound (DUS), with DUS criteria indicating ≥50% diameter stenosis. |
6 months
|
|
Incidence of Target Lesion Revascularization (TLR)
기간: 30 days,6 months,12 months
|
The percentage of enrolled subjects who undergo TLR within 30 days, at 6 months, and at 12 months post-procedure. TLR is defined as any repeat revascularization (including any surgical or percutaneous intervention) of the target lesion after the initial index procedure. |
30 days,6 months,12 months
|
|
Incidence of Ipsilateral Ischemic Stroke
기간: 6 months,12 months
|
Defined as the percentage of enrolled subjects who experience an ipsilateral ischemic stroke at 6 months and 12 months post-procedure. Ipsilateral ischemic stroke is defined as an ischemic stroke occurring in the cerebral hemisphere supplied by the target vessel (the carotid artery treated during the index procedure). |
6 months,12 months
|
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
|
Incidence of Device Deficiencies
기간: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .